Abstract: A carrier assembly includes a front panel, first and second back panels, a card panel, and first and second minor side flaps. The front panel connects to the first and second back panels via opposing fold lines. The card panel connects to one of the second back panel, the front panel, or the first back panel. The second back panel forms a tearable section configured to be at least partially removed from a remainder of the second back panel via at least one frangible connection. The card panel includes information accessible after the tearable section is at least partially removed. The information includes predetermined or variable monetary value. The front panel, the first and second back panels, and the first and second minor side flaps are folded and attached to one or more of the other panels so as to contain the card panel.

Abstract: The present invention provides novel processes and intermediates for preparing corticotropin releasing factor (CRF) receptor antagonists having the structure below which are useful in treating CRF-related disorders such as anxiety and depression.

Abstract: A process is provided for preparing triazole substituted azaindoleoxoacetic piperazine derivative. Novel intermediates produced in the above process, and novel N-1 and amorphous forms of a 1,2,3-triazole substituted azaindoloxoacetic piperazine derivatives and processes for producing such novel forms are also provided.

Abstract: This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.

Abstract: The present invention provides novel processes and intermediates for preparing corticotropin releasing factor (CRF) receptor antagonists having the structure below which are useful in treating CRF-related disorders such as anxiety and depression.